ADARx Pharmaceuticals, Inc. (ADRX) Revenue, Earnings & Financial Statements
$13.82NASDAQ: ADRXMarket Cap $1.53B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
ADARx Pharmaceuticals, Inc. most recently reported annual revenue of $3.0M, a net loss of $73.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$3.0M
Operating Expenses
$92.0M
Operating Profit
−$88.0M
Operating Margin
-2562.1%
Other Income
$15.0M
Interest
$0
Depreciation
$2.0M
Profit Before Tax
−$73.0M
Tax rate (%)
0.0%
Net Profit
−$73.0M
EPS
−$0.97
Quarterly Results — Last 4 Quarters (USD millions)
Metric
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$2.0M
$2.0M
$1.0M
$2.0M
Operating Expenses
$26.0M
$29.0M
$31.0M
$34.0M
Operating Profit
−$25.0M
−$27.0M
−$30.0M
−$32.0M
Operating Margin
-1522.8%
-1264.3%
-4006.8%
-1451.4%
Interest
$0
$0
$0
$0
Profit Before Tax
−$20.0M
−$23.0M
−$26.0M
−$28.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
Net Profit
−$20.0M
−$23.0M
−$26.0M
−$28.0M
EPS
−$1.73
−$0.22
−$0.24
−$0.27
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$508.0M
Current Assets
$493.0M
Cash
$67.0M
Inventory
$0
Receivables
$0
Fixed Assets
$12.0M
Capital Work in Progress
$0
Investments
$413.0M
Other Assets
$0
Total Liabilities
$710.0M
Current Liabilities
$30.0M
Borrowings
$8.0M
Other Liabilities
$702.0M
Equity
$0
Reserves
−$202.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
$262.0M
Investing Cash Flow
−$213.0M
Financing Cash Flow
$0
Net Cash Flow
$52.0M
Free Cash Flow
$259.0M
ADARx Pharmaceuticals, Inc. (ADRX) financials — frequently asked questions
What is ADARx Pharmaceuticals, Inc.'s annual revenue?
ADARx Pharmaceuticals, Inc. (ADRX) reported annual revenue of $3.0M in its most recent fiscal year.
What is ADARx Pharmaceuticals, Inc.'s net profit?
ADARx Pharmaceuticals, Inc. (ADRX) reported a net loss of $73.0M in its most recent fiscal year.
Revenue and earnings of other Biotechnology stocks